Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fabien Maldonado

Pulmonary Disease Nashville, TN Medical Doctor

NPI 1437161221 CMS profile 689175

3601 Tvc, Ste T 1218, Nashville, TN 37232

Open in the dashboard

General payments

$83,346

136 records reported · program years 2019–2025

Research payments

$1,290

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,376,006 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Fabien Maldonado of Nashville, TN is reported in the CMS Open Payments database as having received $83,346 across 136 general payments and $1,290 in research payments paid to them. Separately, studies naming them as principal investigator received $2,376,006 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,281 20
2024 General $21,320 36
2023 General $2,420 17
2022 General $5,271 13
2021 General $12,096 23
2020 General $21,356 15
2020 Research $1,290 1
2019 General $12,602 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fabien Maldonado
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Fabien Maldonado were reported at $8,281. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Fabien Maldonado Pulmonary Disease median Middle half National median
2019 $12,602 $377 $109–$1,340 $163
2020 $21,356 $230 $56–$907 $114
2021 $12,096 $269 $68–$1,072 $132
2022 $5,271 $390 $100–$1,457 $149
2023 $2,420 $419 $114–$1,659 $160
2024 $21,320 $476 $123–$1,818 $164
2025 $8,281 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $34,836 68 payments
  2. Covidien LP $23,112 18 payments
  3. Intuitive Surgical, Inc. $11,515 31 payments
  4. Erbe Elektromedizin GmbH $9,431 2 payments
  5. Pleural Dynamics Inc. $2,133 3 payments
  6. ERBE USA Inc $678 4 payments
  7. Galvanize Therapeutics, Inc $400 1 payment
  8. CSA Medical, Inc $368 1 payment
  9. Steris Corporation $233 1 payment
  10. Noah Medical Corporation $215 1 payment
  11. Other $426 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,848 37 payments
  2. Travel and Lodging $18,874 37 payments
  3. Consulting Fee $8,654 5 payments
  4. Food and Beverage $4,831 55 payments
  5. Education $3,000 1 payment
  6. Gift $140 1 payment
Products named General payments · program years 2019–2025
  1. superDimension Interventional Lung Solutions $23,112 18 payments
  2. ILLUMISITE $16,503 20 payments
  3. Da Vinci Surgical System $10,305 27 payments
  4. superDimension Interventional Lung Solutions $8,170 14 payments
  5. Automatic Continuous Effusion Shunt (ACES) System $2,133 3 payments
  6. Arcpoint $1,473 8 payments
  7. DA VINCI SP $1,210 4 payments
  8. Erbe VIO APC CRYO $459 1 payment
  9. ALIYA SYSTEM $400 1 payment
  10. TruFreeze $233 1 payment
  11. Other $1,678 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Covidien LP $1,290 1 payment

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$47,278

Medicare's payments for the services billed

Medicare patients

212

Average age 71

Services billed

524

113 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 49%
Ischemic heart disease 48%
Cancer 46%
Arthritis 46%
Chronic kidney disease 33%
Depression 31%
Diabetes 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record